TABLE 3.
Effects of GU-DANA, 4-AM-DANA, and DANA on RBC adherence to persistently infected cellsa
| Compound concn (mM) | Mean HAD (102 OD540) ± SD and % binding in presence of:
|
||
|---|---|---|---|
| 4-GU-DANA | DANA | 4-AM-DANA | |
| 5.0 | 0.1 ± 0.16 (1b) | 1.2 ± 0.64 (11) | 3.4 ± 1.20 (30) |
| 2.5 | 0.1 ± 0.15 (1) | 2.3 ± 0.60 (20) | 2.3 ± 0.60 (20) |
| 1.25 | 0.0 ± 0.00 (0) | 2.1 ± 0.21 (18) | 6.6 ± 1.40 (58) |
| 0.5 | 0.1 ± 0.23 (1) | 6.6 ± 1.80 (58) | 6.3 ± 0.60 (56) |
| 0.25 | 0.9 ± 0.40 (8) | 6.0 ± 0.84 (53) | 9.5 ± 1.40 (84) |
| 0.125 | 1.7 ± 0.46 (15) | 9.1 ± 1.90 (80) | 8.2 ± 0.20 (73) |
| 0.05 | 4.3 ± 0.45 (38) | 9.1 ± 1.20 (80) | 11.8 ± 0.70 (104) |
| 0.025 | 6.4 ± 1.25 (57) | 11.8 ± 1.60 (104) | 11.3 ± 1.50 (100) |
| 0 | 11.3 ± 1.20 (100) | 11.3 ± 1.55 (100) | 11.3 ± 1.38 (100) |
a
4-GU-DANA, 4-AM-DANA, and DANA, in concentrations ranging from 0.025 to 5.0 mM, were added to confluent monolayers of persistently infected cells immediately before the addition of a 1% solution of human RBC. Hemadsorption activity (HAD) was determined after 2 h of incubation at 4°C, by lysis and spectrophotometric quantitation of bound RBC.
b
Percent RBC binding, 100% being the value obtained in the absence of compounds.